Efficacy of Commercially Available Topical Cyclosporine A 0.05% in the Treatment of Meibomian Gland Dysfunction

Perry, Henry D.; Doshi-Carnevale, Sima; Donnenfeld, Eric D.; Solomon, Renée; Biser, Seth A.; Bloom, Adam H.

doi:10.1097/01.ico.0000176611.88579.0a

Cited by 145 publications

(95 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1,2 This is supported by the fact that cyclosporine A, a highly potent immunosuppressive agent, improves some of the signs of posterior blepharitis. 28,29 Notably, topical administration of cyclosporine A emulsion has been shown to improve the quality of MG secretion and decrease the number of MG inclusions (plugging) after 2 months of therapy. 28,29 Clearly, both cyclosporine A and azithromycin act to ameliorate MG abnormalities, although their modes of action are different: cyclosporine A affects primarily T lymphocytes, while neutrophils may be the major leukocytic target for azithromycin.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis

Luchs

2008

Adv Therapy

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis

Luchs

2008

Adv Therapy

View full text Add to dashboard Cite

show abstract

“…The most common adverse reactions with instillation are burning and stinging cause compliance only in a minority of patients [64,[78][79][80][81].…”

Section: Cyclosporinementioning

confidence: 99%

“…CsA 0.05 % has dual action in the treatment of dry eye also by decreasing the inflammation in meibomitis that results in an increase in gland secretion [77,78].…”

Section: Cyclosporinementioning

confidence: 99%

The role and treatment of inflammation in dry eye disease

Yağcı

Gürdal

2014

Int Ophthalmol

View full text Add to dashboard Cite

Dry eye syndrome is a common ocular surface problem, affects 10-30 % of the population, especially in those who are older than 40 years. As a consequence of the demographic pressure created by the aging population, its prevalence is expected to increase as well as its burden on ophthalmologic practices. Thus, understanding the complex underlying mechanisms and development of thoughtful, effective strategies that involve these mechanisms are critical. Many factors causing ocular surface damage and inflammation have been shown to contribute to the etiopathogenesis. Increased osmolarity induces ocular surface inflammation leading to disruption of both the quality and quantity of tears. Pathologic tear function and the ocular surface inflammation affects the neural arcade and increases apoptosis in the ocular surface cells thus creating a viscous cycle for dry eye by causing unstable and hyperosmolar tears. Thus, the treatment objective is to prevent severe dry eye complications via preventing inflammation and apoptosis of the ocular surface cells. The ultimate target is a normalized ocular surface, increased tear stability, and decreased osmolarity of the tear film. In the light of current literature, this review aims to elucidate the role of inflammation as the main etiological factor in dry eye disease and discuss current therapeutic approaches to overcome it.

show abstract

“…This is well documented in a recent report by Jang et al 7 It has been suggested that meibomian gland dysfunction can be treated effectively with cyclosporine A 0.05%. [22][23][24] The ocular prosthesis causes mechanical trauma to the tarsal conjunctiva, thus altering the meibomian gland structure. 3,25 Furthermore, poor hygiene with the prosthetic eye can lead to inflammation of the anophthalmic socket.…”

Section: Discussionmentioning

confidence: 99%

Short-term effects of topical cyclosporine A 0.05% (Restasis) in long-standing prosthetic eye wearers: a pilot study

Han

Yoon

Jang

2014

Eye

View full text Add to dashboard Cite

Purpose Long-standing prosthetic eye wearing induces ocular surface inflammation. We investigated the short-term effects of topical cyclosporine A 0.05% (Restasis) in patients with ocular discomfort resulting from long-standing prosthetic eye wearing. Methods This was a prospective, interventional case series. Patients who were unilateral prosthetic eye wearers over a period of 5 years were enrolled at a single institution from March to July 2013. The subjects were instructed to instill topical cyclosporine A 0.05% twice per day. Measurements were made pre-treatment and after 1 and 3 months of treatment. Outcome measures were the ocular symptom score, the lid margin abnormality score, the Schirmer test, and the tear meniscus amount, using Fourier-domain optical coherence tomography. Results In total, 20 consecutive patients (mean age: 60.1 years, 8 males, 12 females) were included. Ocular symptoms were improved after treatment for 1 month in all patients (ocular symptom score pre-treatment 76.83 vs 46.75 after treatment; Po0.001). There was no statistically significant difference in lid margin abnormality score or tear meniscus amount. The Schirmer test results were improved after treatment for 3 months (pre-and after treatment, 6.70 vs 11.40; Po0.001). Conclusions Topical cyclosporine A 0.05% showed a satisfactory effect in long-standing prosthetic eye wearers. Ocular symptoms were markedly relieved in all subjects after treatment for 1 month.

show abstract

Efficacy of Commercially Available Topical Cyclosporine A 0.05% in the Treatment of Meibomian Gland Dysfunction

Abstract: Topical CsA may be helpful in the treatment of meibomian gland dysfunction (posterior blepharitis). Topical CsA did not induce an improvement in the symptoms, but it did decrease the number of meibomian gland inclusions in patients with meibomian gland dysfunction.

Cited by 145 publications

References 24 publications

Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis

Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis

The role and treatment of inflammation in dry eye disease

Short-term effects of topical cyclosporine A 0.05% (Restasis) in long-standing prosthetic eye wearers: a pilot study

Contact Info

Product

Resources

About